Volume 68, Issue 1, Pages (July 2005)

Slides:



Advertisements
Similar presentations
Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Advertisements

Volume 55, Issue 4, Pages (April 1999)
Volume 70, Issue 7, Pages (October 2006)
Volume 66, Issue 6, Pages (December 2004)
Volume 59, Issue 5, Pages (May 2001)
Role of enhanced ceramide generation in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells  Norishi Ueda, Gur P. Kaushal, Xiaoman Hong,
Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells  Zhenmin Ni, Stephen Hou, Cyril H. Barton,
Volume 131, Issue 3, Pages (September 2006)
Keloid Fibroblasts Resist Ceramide-Induced Apoptosis by Overexpression of Insulin- Like Growth Factor I Receptor  Hiroshi Ishihara, Hiroshi Yoshimoto,
Volume 66, Issue 4, Pages (October 2004)
Testosterone promotes apoptotic damage in human renal tubular cells
Volume 70, Issue 7, Pages (October 2006)
Ravinder S. Chana, David C. Wheeler  Kidney International 
Naïve and central memory T-cell lymphopenia in end-stage renal disease
Volume 117, Issue 4, Pages (October 1999)
Volume 58, Issue 5, Pages (November 2000)
Volume 72, Issue 4, Pages (August 2007)
Volume 69, Issue 8, Pages (April 2006)
C.B. Marshall, J.W. Pippin, R.D. Krofft, S.J. Shankland 
Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells  Guillermo Villegas, Bäerbel Lange-Sperandio,
Parenteral iron nephrotoxicity: Potential mechanisms and consequences1
Volume 68, Issue 4, Pages (October 2005)
Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation1  Dr Xiong Z. Ruan, Zac Varghese, Stephen.
Volume 63, Issue 1, Pages (January 2003)
Apoptotic regulatory proteins in renal injury
Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes1  Joerg Plum, Mohammad.
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Volume 57, Issue 3, Pages (March 2000)
Volume 66, Issue 6, Pages (December 2004)
Very low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cells  Edward G. Lynn, Yaw L. Siow, Dr Karmin.
Volume 66, Issue 5, Pages (November 2004)
Volume 59, Issue 5, Pages (May 2001)
Volume 62, Issue 3, Pages (September 2002)
Inhibition of glomerular cell apoptosis by heparin
PDGF regulates gap junction communication and connexin43 phosphorylation by PI 3- kinase in mesangial cells  Jian Yao, Tetsuo Morioka, Takashi Oite  Kidney.
Volume 59, Issue 5, Pages (May 2001)
Volume 68, Issue 4, Pages (October 2005)
Volume 65, Issue 5, Pages (May 2004)
Comorbidity and confounding in end-stage renal disease
Volume 54, Issue 2, Pages (August 1998)
Sri Rajalakshmi Rudrabhatla, Christie L. Mahaffey, Mark E. Mummert 
Volume 60, Issue 6, Pages (December 2001)
Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity  Debendranath Banerjee, Marilis Rodriguez, Mihir.
Volume 66, Issue 6, Pages (December 2004)
Volume 56, Issue 1, Pages (July 1999)
Volume 55, Issue 4, Pages (April 1999)
Volume 70, Issue 12, Pages (December 2006)
Volume 67, Pages S51-S58 (June 2005)
Volume 58, Issue 1, Pages (July 2000)
Volume 69, Issue 1, Pages (January 2006)
Volume 65, Issue 6, Pages (June 2004)
Volume 80, Issue 2, Pages (July 2011)
Volume 87, Issue 1, Pages (January 2015)
Volume 56, Pages S137-S140 (July 1999)
Tumor necrosis factor-α and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells  Udo K. Meßmer, Verena A. Briner, Josef.
James Gailit, Mary J. Marchese, Richard R. Kew, Barry L. Gruber 
Volume 55, Issue 6, Pages (June 1999)
Volume 55, Issue 2, Pages (February 1999)
Volume 70, Issue 3, Pages (August 2006)
Silvia Selleri, Holger Seltmann, Silvia Gariboldi, Yuri F
Lu-Cheng Cao, Thomas Honeyman, Julie Jonassen, Cheryl Scheid 
Volume 54, Issue 4, Pages (October 1998)
Volume 68, Issue 1, Pages (July 2005)
Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action  Markus Meissner, Monika.
Volume 58, Issue 1, Pages (July 2000)
Volume 56, Issue 1, Pages (July 1999)
Volume 68, Issue 1, Pages (July 2005)
Lipoprotein abnormalities in diabetic nephropathy
Volume 57, Issue 6, Pages (June 2000)
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Presentation transcript:

Volume 68, Issue 1, Pages 173-178 (July 2005) Carbamylated low-density lipoprotein induces death ofendothelial cells: A link to atherosclerosis in patients with kidney disease  Ercan Ok, Alexei G. Basnakian, Eugene O. Apostolov, Yousri M. Barri, Sudhir V. Shah  Kidney International  Volume 68, Issue 1, Pages 173-178 (July 2005) DOI: 10.1111/j.1523-1755.2005.00391.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Characterization of chemically prepared carbamylated low-density lipoprotein (cLDL). (A) Mobility of cLDL (visualized by a Sudan Black staining) in agarose gel is increased compared to native LDL (nLDL). (B) In vitro cLDL has increase portion of homocitrulline (carbamyl lysine), but is not oxidized as measured by the malondialdehyde (MDA) content. Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Morphologic changes and cell death induced in human coronary artery endothelial cells (HCAECs) by carbamylated low-density lipoprotein (cLDL). Cells treated with 200 μg/mL cLDL show morphologic signs of deterioration compared to cells treated with the same amount of native LDL (nLDL) (upper panels). The cells are smaller than normal, shrunken, and some of them are detached from the plate. The monolayer is disrupted (areas of cell-free surface shown by arrows). Spaces between cells are filled with cellular debris. Treatment of endothelial cells with cLDL, but not nLDL induced cell death measured by lactate dehydrogenase (LDH) release (lower panels). Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Carbamylated low-density lipoprotein (cLDL)-induced human coronary artery endothelial cell (HCAEC) death is dependent on the degree of carbamylation and the time of exposure with cLDL. (A) Native LDL was carbamylated to different degrees as described in the Methods section by varying the time of the exposure with potassium cyanate, which was then removed by excessive dialysis. HCAECs were exposed with the resulting cLDL (200 μg/mL) for 24 hours and cell death was measured by lactate dehydrogenase (LDH) release. (B) Time course of cLDL (200 μg/mL) treatment of HCAECs. Cell death was assessed by LDH release. Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Apoptosis of human coronary artery endothelial cells (HCAECs) induced by carbamylated low-density lipoprotein (cLDL). Cells were treated with 200 μg/mL LDL isoforms for 16 hours and apoptosis was measured using annexin V/propidium iodide staining. The number of apoptotic cells (AV+/PI-) was detected by fluorescence-activated cell sorting (FACS) analysis. Each point is the mean ± SEM for N = 4 to 6. *P < 0.01. nLDL is native low-density lipoprotein. Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Dose-dependent induction of human coronary artery vascular smooth muscle cell (CASMC) proliferation by carbamylated low-density lipoprotein (cLDL). CASMCs were cultured and treated with cLDL or native LDH (nLDL) and proliferation was measured by bromodeoxyuridine (BrdU) assay as described in the Methods section. Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Increase of total plasma protein carbamylation and plasma carbamylated low-density lipoprotein (cLDL) concentration in end-stage renal disease (ESRD) patients on hemodialysis. (A) Plasma protein carbamylation was measured by homocitrulline assay as described in the Methods section in a group of control individuals (N = 11) and a group of ESRD patients on hemodialysis (N = 13). *P < 0.01. (B) cLDL was determined using enzyme-linked immunosorbent assay (ELISA) in the same groups. Results are given as absorbance at 450nm. **P < 0.001. Kidney International 2005 68, 173-178DOI: (10.1111/j.1523-1755.2005.00391.x) Copyright © 2005 International Society of Nephrology Terms and Conditions